- Home
- SEER vs TNXP Comparison
SEER vs TNXP Comparison
Compare SEER & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- TNXP
- Stock Information
- Founded
- SEER 2017
- TNXP 2007
- Country
- SEER United States
- TNXP United States
- Employees
- SEER N/A
- TNXP N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- TNXP Health Care
- Exchange
- SEER Nasdaq
- TNXP Nasdaq
- Market Cap
- SEER 124.9M
- TNXP 116.9M
- IPO Year
- SEER 2020
- TNXP N/A
- Fundamental
- Price
- SEER $1.97
- TNXP $15.71
- Analyst Decision
- SEER Hold
- TNXP Strong Buy
- Analyst Count
- SEER 1
- TNXP 2
- Target Price
- SEER $3.00
- TNXP $585.00
- AVG Volume (30 Days)
- SEER 271.4K
- TNXP 1.5M
- Earning Date
- SEER 05-07-2025
- TNXP 05-12-2025
- Dividend Yield
- SEER N/A
- TNXP N/A
- EPS Growth
- SEER N/A
- TNXP N/A
- EPS
- SEER N/A
- TNXP N/A
- Revenue
- SEER $14,170,000.00
- TNXP $10,094,000.00
- Revenue This Year
- SEER $23.54
- TNXP $12.17
- Revenue Next Year
- SEER $42.98
- TNXP $789.15
- P/E Ratio
- SEER N/A
- TNXP N/A
- Revenue Growth
- SEER N/A
- TNXP 29.94
- 52 Week Low
- SEER $1.56
- TNXP $6.76
- 52 Week High
- SEER $2.63
- TNXP $672.00
- Technical
- Relative Strength Index (RSI)
- SEER 52.65
- TNXP 44.80
- Support Level
- SEER $1.97
- TNXP $15.23
- Resistance Level
- SEER $2.15
- TNXP $22.25
- Average True Range (ATR)
- SEER 0.11
- TNXP 2.36
- MACD
- SEER 0.04
- TNXP -0.54
- Stochastic Oscillator
- SEER 66.04
- TNXP 16.54
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.